The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin

Blood

Volumn 90, Issue 5, 1997, Pages 1874-1882

  Van Meijer, Marja ^b   Smilde, Annelies ^b   Tans, Guido ^b   Nesheim, Michael E ^b   Pannekoek, Hans ^b   Horrevoets, Anton J G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE INHIBITOR; THROMBIN; VITRONECTIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; REACTION ANALYSIS; SUICIDE;

EID: 0030954682     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.1874     Document Type: Article

References (48)

1. Van Meijer M, Pannekoek H: Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. (Review). Fibrinolysis 9:263, 1995
2. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ: Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 83:6776, 1986
3. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Mourik JA: Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 5:2539, 1986
4. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV, Gelehrter TD: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 78:1673, 1986
5. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Dano K: Plasminogen activator inhibitor type-1: Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 209:213, 1986
6. Ehrlich HJ, Keijer J, Preissner KT, Klein Gebbink R, Pannekoek H: Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 30:1021, 1991
7. Ehrlich HJ, Klein Gebbink R, Keijer J, Linders M, Preissner KT, Pannekoek H: Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265:13029, 1990
8. Ehrlich HJ, Klein Gebbink R, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H: Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 115:1773, 1991
9. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF: Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339:721, 1989
10. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF, Bassel-Duby RS: Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 87:3530, 1990
11. Madison EL, Goldsmith EJ, Gething MJ, Sambrook JF, Gerard RD: Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem 265:21423, 1990
12. Van Meijer M, Roelofs Y, Neels J, Horrevoets AJG, van Zonneveld A-J, Pannekoek H: Selective screening of a large phage-display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator. J Biol Chem 271:7423, 1996
13. Horrevoets AJG, Tans G, Smilde AE, van Zonneveld AJ, Pannekoek H: Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1. J Biol Chem 268:779, 1993
14. Walsh CT: Suicide substrates, mechanism-based enzyme inactivators: recent developments. (Review). Annu Rev Biochem 53:493, 1984
15. Waley SG: Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem J 227:843, 1985
16. Knight, CG: The characterization of enzyme inhibition, in Barrett AJ and Salvesen G (eds): Proteinase Inhibitors. Amsterdam, The Netherlands, Elsevier, 1986, p 23
17. Patston PA, Gettins P, Beechem J, Schapira M: Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30:8876, 1991
18. Audenaert AM, Knockaert I, Collen D, Declerck PJ: Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J Biol Chem 269:19559, 1994
19. Olson ST: Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of α-thrombin. J Biol Chem 260:10153, 1985
20. Björk I, Nordling K, Larsson I, Olson ST: Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. J Biol Chem 267:19047, 1992
21. Urano T, Strandberg L, Johansson LB, Ny T: A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 209:985, 1992
22. Björk I, Ylinenjärvi K, Olson ST, Bock PE: Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor. J Biol Chem 267:1976, 1992
23. Patston PA, Gettins PGW, Schapira M: Serpins are suicide substrates: Implications for the regulation of proteolytic pathways. Semin Thromb Hemost 20:410, 1994
24. Marcum JA, Rosenberg RD: Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 126:365, 1985
25. Mimuro J, Schleef RR, Loskutoff DJ: Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 70:721, 1987
26. Nesheim ME, Prendergast FG, Mann KG: Interactions of a fluorescent active-site-directed inhibitor of thrombin: Dansylarginine N-(3-Ethyl-1,5-pentandiyl)amide. Biochemistry 18:996, 1979
27. Kettner C, Shaw E: D-Phe-Pro-ArgCH2Cl-A selective affinity label for thrombin. Thromb Res 14:969, 1979
28. Di Scipio RG, Hermodson MA, Yates SG, Davie EW: A comparison of human prothrombin, Factor IX (Christmas Factor), Factor X (Stuart Factor), and Protein S. Biochemistry 16:698, 1977
29. Pletcher CH, Nelsestuen GL: The rate-determining step of the heparin-catalyzed antithrombin/thrombin reaction is independent of thrombin. J Biol Chem 257:5342, 1982
30. Nesheim ME: A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. J Biol Chem 258:14708, 1983
31. Bjorquist P, Brohlin M, Ehnebom J, Ericsson M, Kristiansen C, Pohl G, Deinum J: Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta 1209:191, 1994
32. Klein Gebbink R, Reynolds CH, Tollefsen DM, Mertens K, Pannekoek H: Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry 32:1675, 1993
33. Nesheim ME, Furmaniak-Kazmierczak E, Henin C, Côté G: On the existence of platelet receptors for Factor V(a) and Factor VIII(a). Thromb Haemost 70:80, 1993
34. Declerck PJ, De Mol M, Vaughan DE, Collen D: Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 267:11693, 1992
35. Nesheim M, Blackburn MN, Lawler CM, Mann KG: Dependance of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin. J Biol Chem 261:3114, 1986
36. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D: Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 268:12367, 1993
37. Podack ER, Dählback B, Griffin JH: Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. J Biol Chem 261:7387, 1986
38. Salonen EM, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E: Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264:6339, 1989
39. Patston PA, Schapira M: Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin. Blood 84:1164, 1994
40. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-Å, Ny T: Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: Conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 34:13833, 1995
41. Hoylaerts M, Rijken DC, Lijnen HR, Collen D: Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912, 1982
42. Le Bonniec BF, Esmon CT: Glu-192 to Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci USA 88:7371, 1991
43. Berk BC, Taubman MB, Cragoe EJ Jr, Fenton JW II, Griendling KK: Thrombin signal transduction mechanisms in rat vascular smooth muscle cells: Calcium and protein kinase C-dependent and -independent pathways. J Biol Chem 265:17334, 1990
44. Taubman MB: Tissue factor regulation in vascular smooth muscle: A summary of studies performed using in vivo and in vitro models. [Review]. Am J Cardiol 72:55, 1993 (suppl C)
45. Nelken NA, Soifer SJ, O'Keefe J, Vu T-KH, Charo IF, Coughlin SR: Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614, 1992
46. Wojta J. Gallicchio M, Zoellner H, Hufnagl P, Last K, Filonzi EL, Binder BR, Hamilton JA, McGrath K: Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 70:469, 1993
47. Noda-Heiny H, Fujii S, Sobel BE: Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. Circ Res 72:36, 1993
48. Stefansson S, Lawrence DA, Argraves WS: Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 271:8215, 1996